Notices. Notice

232 words·~1 min read·/register/2020/04/07/2020-07262

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2020-N-0626] Pulmonary-Allergy Drugs Advisory Committee; Postponed AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC) scheduled for April 21, 2020, is postponed. The Food and Drug Administration (FDA), like other government agencies, is taking the necessary steps to ensure the Agency is prepared to continue our vital public health mission in the event that our day-to-day operations are impacted by the COVID-19 public health emergency.

Therefore, we are canceling or postponing all non-essential meetings through the month of April. We will reassess on an ongoing basis for future months. Therefore, this meeting is being postponed. The meeting was announced in the **Federal Register** on February 20, 2020. FOR FURTHER INFORMATION CONTACT: LaToya Bonner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax: 301-847-8533, email: *PADAC@fda.hhs.gov,* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area.

Please call the Information Line for up-to-date information on this meeting, which was announced in the **Federal Register** of February 20, 2020 (85 FR 9780). Dated: April 1, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2020-07262 Filed 4-6-20; 8:45 am]